- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
FDA Approves Relacorilant for Ovarian, Fallopian, and Peritoneal Cancer
Mar 27, 2026
Ion Channel Modulators Market - Segmentation, Manufacturing Cost Analysis Including Key Raw Materials, Price Trend, Key Suppliers and Forecast 2027
Mar 09, 2021
North America Vaccines Market is Estimated to Grow with a CAGR of 6.0% from 2019-2027
Sep 25, 2020
Former Deputy Head of China's Drug Regulator Sentenced to 16 Years in Prison
Nov 15, 2019
Malaria Treatment Market is expected to reach US$ 24,487.73 million by 2030
Nov 02, 2023
United Cannabis Corporation Receives Notice of Allowance for New Patent Covering Methods of Preparing and Using Cannabinoid Formulations
Dec 12, 2019
Enteral and Parenteral Medical Nutrition Market is expected to reach US$ 25,476.86 million by 2028
Jun 15, 2023
Follow us on
